Innovative FEED Act of 2025
HB2203, the Innovative FEED Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to create a new category called “zootechnical animal food substances.” These are substances added to animal feed or drinking water that are intended to affect digestive byproducts, reduce foodborne pathogens in food animals, or alter an animal’s gastrointestinal microbiome to affect body structure or function, so long as the effect occurs only within the gastrointestinal tract. The bill excludes substances intended to diagnose, cure, mitigate, treat, or prevent disease; hormones; certain approved or investigated animal drug active ingredients; ionophores; and other substances the Secretary excludes by rule.
The bill would treat these substances as food additives rather than drugs, and would require them to go through the food additive petition and regulation process under section 409 of the FDCA. Petitioners would have to submit data on the intended effect, the amount needed to achieve it, and full reports of investigations. FDA would be authorized to issue regulations setting the conditions under which the substance may be safely used and, specifically for zootechnical substances, the conditions under which they may be used to achieve the intended effect. The bill also requires labeling to state that the substance is not for disease diagnosis, cure, mitigation, treatment, or prevention, while allowing claims about the intended effect on animal structure or function. It further amends the misbranding provisions so animal food lacking the required statement would be misbranded.
In practical terms, the bill would change how certain feed additives are regulated under federal law by creating a clearer pathway for products aimed at animal health, digestion, microbiome effects, and pathogen reduction without classifying them as animal drugs. It would affect manufacturers, feed companies, livestock producers, and FDA’s review process, while preserving FDA oversight through food additive regulation and labeling requirements. The bill also states that nothing in it authorizes HHS to require the use of any zootechnical food substance or food additive.
The available legislative context shows no recorded committee debate or votes yet, and the bill was simply referred to the House Committee on Energy and Commerce. Based on the bill’s bipartisan list of original cosponsors, the measure appears to have some cross-party support and is framed as a regulatory modernization and economic development bill for animal agriculture. Because there are no transcripts or votes, there is no documented opposition in the provided materials, but the main policy issue is the line it draws between food additives and animal drugs, and whether the new category could broaden or streamline approval for feed-based animal health products.
HB2203 would amend sections 201, 403, and 409 of the Federal Food, Drug, and Cosmetic Act to add a new statutory category for zootechnical animal food substances, require FDA food-additive review for those substances, impose specific petition and labeling requirements, and make noncompliant labeling a misbranding issue. It would affect federal regulation of animal feed additives, especially products used in livestock and poultry production to influence digestion, microbiomes, or pathogen levels, while expressly preserving FDA’s authority to regulate safety and not mandating use of any such substance.
The bill appears to have a generally favorable or at least constructive reception in the limited record provided. Its bipartisan sponsorship suggests support from members interested in animal agriculture, feed innovation, and regulatory clarity. No committee testimony or votes are available, so there is no documented opposition in the supplied materials, but the bill is presented as a modernization measure rather than a controversial policy shift.
The central point of contention is likely the regulatory classification of these products: whether substances intended to alter animal digestion, microbiomes, or pathogen levels should be treated as food additives rather than animal drugs. Supporters appear to favor a clearer, more predictable approval pathway for feed innovation and livestock productivity, while potential critics may worry about safety oversight, labeling adequacy, or whether the new category could blur the boundary between feed additives and drugs. The bill also preserves FDA discretion to exclude substances by rule, which may be important to stakeholders concerned about scope.